Conference Coverage
about 1 month ago
Jamie Michael, MD, discusses MRI and genomics in active surveillanceabout 2 months ago
Matthew Truesdale, MD, on IsoPSA performance with and without mpMRILatest News
Aug 18, 2026 | Opinion
Hans Arora, MD, PhD, on improving communication in the OR
Radium-223 fails to improve skeletal event-free survival in metastatic RCC
Aug 18, 2026
SBRT improves multiple quality of life domains but not DFS vs MH-IMRT
Aug 18, 2026
HoLEP learning curve and strategies for successful adoption, with Daniel S. Kellner, MD
Aug 17, 2026
FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC
Aug 17, 2026
Advertisement
Shorts
0:32
IVF-related incontinence: When to reassure vs refer
21 hours ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
0:36
Adjuvant pembrolizumab in RCC: Counseling patients on long-term toxicity
5 days ago
by
Elizabeth Nally, MBBS
0:46
Testosterone therapy in women: Rethinking pre- and postmenopausal categories
7 days ago
by
Jessica M. Yih, MD
0:21
IVF and voiding symptoms: Start with cycle timing
8 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
1:01
The UroOnc Minute: The importance of BCG maintenance in NMIBC
9 days ago
by
Adam B. Weiner, MD(+1 more)
1:04
Keith Xavier, MD, URPS, shares early experience with Altaviva for male urge incontinence
12 days ago
by
Keith Xavier, MD, URPS
1:09
Adam B. Murphy, MD, MBA, MSCI, urges thoughtful AI integration to prevent clinician burnout
13 days ago
by
Adam B. Murphy, MD, MBA, MSCI
0:36
Joshua Lang, MD, MS, on matching treatment intensity to tumor biology
14 days ago
by
Joshua Lang, MD, MS
0:36
Joshua Halpern, MD, on the advantages of mail-in semen analysis
15 days ago
by
Joshua Halpern, MD, MS
0:59
EV/pembro approval: Translating the science into global care
16 days ago
by
María Natalia Gandur Quiroga, MD, MSc
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Ryan K. Flannigan, MD, discusses phase 2 data showing promising efficacy with sustained-release lidocaine in men with chronic scrotal pain.
A recent study found active surveillance use for low-risk prostate cancer rose from 27% to 93% among veterans from 2005 to 2024.
A national analysis found that 51% of focal therapy procedures for prostate cancer occurred in patients with low-, high-, or very-high-risk disease, outside current guideline-supported settings.
The DIRECT-AI registry has enrolled its first patient to prospectively assess how the ArteraAI Prostate Test influences treatment decisions and outcomes in routine care.
Belzutifan plus lenvatinib significantly improved progression-free survival vs cabozantinib in patients with previously treated advanced clear cell renal cell carcinoma.
Nima Almassi, MD, reviews long-term evidence for bladder preservation after systemic therapy in muscle-invasive bladder cancer.
Functional reconstructive urology emerged gradually as anatomical success proved insufficient—enabled by urodynamics, neurourology, and institutional milestones, according to Sasha Vereecken, BScN, RN.
An analysis of NHANES data found that higher intake of ultra-processed foods was associated with increased prostate cancer risk among US men.
In this episode of Pearls & Perspectives, Amy Pearlman, MD, and plastic surgeon Andrew T. Cohen, MD, FACS, discuss managing patient expectations and the importance of cultivating balance outside of surgical practice.
Narmina Khanmammadova, MD, discusses interim findings on preoperative pelvic floor therapy and its potential to improve continence recovery after HoLEP.
Advertisement
Jessica Yih, MD, reviews evidence on testosterone therapy for female sexual dysfunction, highlighting promising but limited data in premenopausal women.
A claims-based analysis found blue light cystoscopy was associated with increase health care resource utilization in NMIBC without significantly increasing total costs.
A real-world analysis found that achieving a PSA level below 0.2 ng/mL was associated with improved overall survival in mCSPC.
These FAQs highlight key recommendations and practical takeaways from the 2026 AUA/ASTRO Clinically Localized Prostate Cancer guideline amendment.
The phase 3 PSMAddition trial found that adding lutetium Lu 177 vipivotide tetraxetan to ADT and an ARPI significantly improved rPFS in mHSPC.
Advertisement
Advertisement
Trending on Urology Times
1
Radium-223 fails to improve skeletal event-free survival in metastatic RCC
2
Hans Arora, MD, PhD, on improving communication in the OR
3
FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC
4
Active surveillance use for low-risk prostate cancer reaches 93% in VA System
5